Changes in circulating microRNA levels associated with prostate cancer
By R. Bryant, T. Pawlowski, J. Catto, G. Marsden, R. Vessella, B. Rhees, C. Kuslich, T. Visakorpi, F. Hamdy. British Journal of Cancer, 2012
708 citations recorded by the source corpus.
Background:The aim of this study was to investigate the hypothesis that changes in circulating microRNAs (miRs) represent potentially useful biomarkers for the diagnosis, staging and prediction of outcome in prostate cancer.Methods:Real-time polymerase chain reaction analysis of 742 miRs was performed using plasma-derived circulating microvesicles of 78 prostate cancer patients and 28 normal control individuals to identify differentially quantified miRs.Results:A total of 12 miRs were differentially quantified in prostate cancer patients compared with controls, including 9 in patients without metastases. In all, 11 miRs were present in significantly greater amounts in prostate cancer patients with metastases compared with those without metastases. The association of miR-141 and miR-375 with metastatic prostate cancer was confirmed using serum-derived exosomes and microvesicles in a separate cohort of patients with recurrent or non-recurrent disease following radical prostatectomy. An analysis of five selected miRs in urine samples found that miR-107 and miR-574-3p were quantified at significantly higher concentrations in the urine of men with prostate cancer compared with controls.Conclusion:These observations suggest that changes in miR concentration in prostate cancer patients may be identified by analysing various body fluids. Moreover, circulating miRs may be used to diagnose and stage prostate cancer.
Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/9bf2161e2af7c8ae623e880c96869927341a02f8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Quantitative and stoichiometric analysis of the microRNA content of exosomes (2014, background): “Multiple independent studies have reported that exosomes contain miRNA, and exosomes have been proposed to be treasure chests for biomarker applications (22, 26).”
- MicroRNA (miRNA) in cancer (2015, background): “Similarly, the prognostic value of increased expression levels of circulating miR-141 and miR-375 correlating with low-risk through high-risk and from localized to metastatic prostate cancer was documented [71,72].”
- Characterization of human plasma-derived exosomal RNAs by deep sequencing (2013, background): “The association of exosomal miR141 and miR-375 with metastatic prostate cancer has been confirmed in a cohort of patients with recurrent or nonrecurrent cancer following radical prostatectomy [42].”
- Assessing sample and miRNA profile quality in serum and plasma or other biofluids. (2013, methodology): “To facilitate discovery and clinical development of miRNA-based biomarkers, we developed a genomewide Locked Nucleic Acid (LNA™)-based miRNA qPCR platform with unparalleled sensitivity and robustness.”
- Extracellular vesicles in cancer: cell-to-cell mediators of metastasis (2016, background): “Several miRNAs are differentially expressed in circulating tumor exosomes from prostate cancer, compared to controls (Bryant et al., 2012; Li et al., 2016).”
- Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease (2019, background): “While these reports have only analyzed whole plasma/serum, miR-375 is thought to be both carried in EVs (Bryant et al., 2012; Zaharie et al., 2015) and associated with HDL (Vickers et al.”